By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related conditions from CSPC Pharmaceutical Group and collaborate on other projects, ...

In return for the ex-China rights to all eight programs as well as use of CSPC’s AI molecular design capabilities and LiquidGel once-monthly dosing platform technology, AstraZeneca is making the $1.2 ...

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...

AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC ...

AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstaZeneca shares with a much-needed fillip on Monday. Having slumped almost 20% from March highs, ...